Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 30,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the sale, the executive vice president now owns 57,114 shares in the company, valued at approximately $4,512,006. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Gilead Sciences, Inc. (NASDAQ GILD) traded up $1.23 during midday trading on Tuesday, reaching $80.25. 11,750,000 shares of the company’s stock traded hands, compared to its average volume of 8,040,000. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The stock has a market capitalization of $104,800.00, a price-to-earnings ratio of 9.13, a price-to-earnings-growth ratio of -1.68 and a beta of 1.13. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.75 earnings per share. research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.59%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.
Several research firms have recently issued reports on GILD. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $79.02 to $96.00 in a research report on Tuesday. Mizuho reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. BMO Capital Markets reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, January 3rd. Finally, Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $85.61.
A number of hedge funds and other institutional investors have recently bought and sold shares of GILD. BlackRock Inc. boosted its stake in shares of Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after purchasing an additional 310,607 shares during the period. FMR LLC boosted its stake in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares during the period. 75.95% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://transcriptdaily.com/2018/01/16/gilead-sciences-inc-gild-evp-sells-2370000-00-in-stock.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.